OnCo

Osteosarcoma: lines of therapy

Cancer page →

4 standard-of-care settings across 4 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Screening, prevention and diagnosis1
Early / localised1
Advanced, first line1
Second line1

Screening, prevention and diagnosis

SubgroupSettingApproachProducts and trialsEvidence
All comersMetastatic at diagnosisSame chemotherapy with resection of all metastases (thoracotomy) when feasible; survival ~25-30%.81

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersLocalised high-gradeNeoadjuvant MAP (methotrexate, doxorubicin, cisplatin) ×2 cycles, limb-salvage resection with wide margins (amputation if required), adjuvant MAP to ~29 weeks; mifamurtide added in EU.81

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersUnresectable / axialCarbon-ion or proton radiotherapy for craniofacial and pelvic tumours; Sm-153 or Ra-223 for bone-forming metastases (investigational).77

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersRelapsedSurgical resection of recurrence; ifosfamide ± etoposide, gemcitabine-docetaxel; regorafenib or cabozantinib; clinical trials (CAR-T, ADCs).95

Regimens in the library

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.